TransMedics Group, Inc. (NASDAQ:TMDX) CFO Stephen Gordon Sells 15,000 Shares

TransMedics Group, Inc. (NASDAQ:TMDX) CFO Stephen Gordon sold 15,000 shares of TransMedics Group stock in a transaction that occurred on Monday, May 6th. The shares were sold at an average price of $128.00, for a total transaction of $1,920,000.00. Following the completion of the transaction, the chief financial officer now owns 23,299 shares of the company’s stock, valued at $2,982,272. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

Stephen Gordon also recently made the following trade(s):

• On Monday, April 1st, Stephen Gordon sold 15,000 shares of TransMedics Group stock. The shares were sold at an average price of $74.01, for a total value of $1,110,150.00.
• On Friday, March 8th, Stephen Gordon sold 1,903 shares of TransMedics Group stock. The stock was sold at an average price of $87.63, for a total value of $166,759.89.
• On Monday, March 4th, Stephen Gordon sold 15,000 shares of TransMedics Group stock. The stock was sold at an average price of $82.80, for a total transaction of $1,242,000.00.

TransMedics Group Trading Down 0.0 %

Shares of TMDX stock traded down $0.06 during trading hours on Wednesday, reaching $127.22. The company’s stock had a trading volume of 637,458 shares, compared to its average volume of 769,221. The company has a current ratio of 9.72, a quick ratio of 8.76 and a debt-to-equity ratio of 3.18. The stock has a market capitalization of $4.19 billion, a P/E ratio of -374.35 and a beta of 1.87. The firm’s fifty day simple moving average is $87.41 and its 200 day simple moving average is $78.57. TransMedics Group, Inc. has a one year low of $36.42 and a one year high of $132.96.

TransMedics Group (NASDAQ:TMDX) last released its quarterly earnings results on Tuesday, April 30th. The company reported $0.35 earnings per share for the quarter, beating the consensus estimate of ($0.05) by $0.40. The company had revenue of $96.90 million for the quarter, compared to analyst estimates of $83.78 million. TransMedics Group had a positive return on equity of 7.95% and a negative net margin of 3.43%. The firm’s revenue was up 132.9% on a year-over-year basis. During the same period in the previous year, the company posted ($0.08) earnings per share. Equities research analysts expect that TransMedics Group, Inc. will post 0.62 EPS for the current year.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the business. Venturi Wealth Management LLC bought a new stake in shares of TransMedics Group in the 1st quarter worth approximately $30,000. Fidelis Capital Partners LLC purchased a new stake in shares of TransMedics Group in the first quarter worth $35,000. Cutler Group LLC CA increased its holdings in shares of TransMedics Group by 600.0% during the third quarter. Cutler Group LLC CA now owns 700 shares of the company’s stock valued at $38,000 after acquiring an additional 600 shares in the last quarter. RiverPark Advisors LLC purchased a new position in shares of TransMedics Group in the 3rd quarter worth about $60,000. Finally, First Horizon Advisors Inc. boosted its stake in TransMedics Group by 26.8% in the 4th quarter. First Horizon Advisors Inc. now owns 1,049 shares of the company’s stock worth $83,000 after purchasing an additional 222 shares in the last quarter. 99.67% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several analysts have issued reports on the company. Oppenheimer upped their target price on TransMedics Group from $105.00 to $125.00 and gave the stock an “outperform” rating in a research note on Wednesday, May 1st. Morgan Stanley lifted their target price on shares of TransMedics Group from $75.00 to $95.00 and gave the stock an “equal weight” rating in a research report on Wednesday, February 28th. Piper Sandler reaffirmed an “overweight” rating and set a $120.00 price objective (up from $95.00) on shares of TransMedics Group in a research note on Wednesday, May 1st. TD Cowen boosted their target price on TransMedics Group from $100.00 to $130.00 and gave the company a “buy” rating in a research note on Wednesday, May 1st. Finally, JPMorgan Chase & Co. raised their price target on TransMedics Group from $105.00 to $127.00 and gave the stock an “overweight” rating in a research report on Wednesday, May 1st. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $119.00.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.